GI - Colorectal cancer Flashcards
(44 cards)
CRC
Epidemiology
Typical sites
Modes of metastasis
Epidemiology:
- > 90% of CRC occurs in patients age ≥ 50
- M: F ratio = 1.3: 1
- Commonest cancer in Hong Kong
- 2nd leading cause of cancer death in both males and females
Typical sites: Majority of CRC are left-sided cancer
- Ascending colon = 25%
- Transverse colon = 10%
- Descending colon = 15%
- Sigmoid = 20%
- Rectum = 30%
Modes of metastasis: Hematogenous/ Lymphatic/ Contiguous/ Transperitoneal
- Liver is usually the first site of metastasis since the venous drainage of intestinal tract
is via the portal venous system
- Lung can be the first site of metastasis for tumours in distal rectum since inferior rectal veins drains into IVC rather than portal venous system
CRC
Risk factors
Non-modifiable:
- Asian or Ashkenazi Jews
- Old age
Past medical history (PMH)
- Previous colorectal cancer (CRC)
- Colonic adenomatous polyps
- Hereditary colorectal cancer syndrome
* Familial adenomatous polyposis (FAP)
* Hereditary non-polyposis colorectal cancer (HNPCC) (Lynch syndrome)
* Familial juvenile polyposis
* MYH-associated polyposis
* Hamartoma polyposis
- Inflammatory bowel disease
- Obesity
- Diabetes mellitus (DM)
Family history:
- Colorectal cancer (4x risk)
- Colonic adenomatous polyps
Social history:
- Smoking
- Alcoholism
- Lack of physical exercise
- Dietary lifestyle
* Red and processed meat
* Lack of dietary fibers
* High temperature cooking
Familial adenomatous polyposis (FAP)
Inheritance
Variants
Genetic cause
Disease course
Inheritance:
- Autosomal dominant (AD) syndrome
- Up to 25% present without other affected family members
Variants:
- Gardner’s syndrome = FAP associated with extracolonic manifestation
- Turcot’s syndrome = FAP associated with CNS tumours
- Attenuated FAP = < 100 adenomatous colorectal polyps at presentation
Genetics:
- germline mutations in adenomatous polyposis coli (APC) gene on chromosome 5
- APC gene is a tumour suppressor gene
Disease course:
- Polyp and symptoms appear at an average age of 16 (2nd – 3rd decades of life)
- Colorectal cancer occurs in 90% of untreated individuals at the age of 45 and approaches ~100% by 50 years old
- > 100 adenomatous colorectal polyps
- Adenomatous polyps do NOT have high malignant potential individually
- Increased risk of CRC due to vast number of adenomatous polyps
Familial adenomatous polyposis (FAP)
Extracolonic manifestations
Familial adenomatous polyposis (FAP)
Investigations
Investigation: Mainly by colonoscopy
- Colonoscopy showing > 100 polyps in addition to extra-colonic tumours of duodenum and
pancreas (ampullary carcinoma)
Genetic testing:
- APC genetics testing of at-risk family members
Surveillance:
- Flexible sigmoidoscopy every 1 year (annual) starting at age 12
- OGD every 1 – 3 years starting at age 25: for adenocarinoma in any part of GIT especially duodenum
Familial adenomatous polyposis (FAP)
Treatment options
Surgical treatment:
Total proctocolectomy with end ileostomy
Total proctocolectomy with ileal-pouch anal anastomosis (IPAA):
- Indicated for profuse polyposis without rectal sparing/ >10 rectal adenomas
- Indicated for mesenteric desmoid tumours (cannot convert IRA to IPAA later due to shortened mesentery)
- Higher risk of bleeding and infertility in women
Total abdominal colectomy with ileorectal anastomosis (IRA)
- Indicated if rectal sparing/ <10 rectal adenoma + all polyps managed endoscopically by colonoscopic snare excision
- May progress to severe rectal polyposis and require a secondary proctectomy
Hereditary non-polyposis colorectal cancer (HNPCC)
Inheritance
Genetic cause
Disease course
Inheritance:
- Autosomal dominant (AD) syndrome
Genetic cause: Amsterdam criteria for Lynch syndrome
- patients and family with a germline mutation in one of the DNA mismatch repair (MMR) genes: MLH1 (90%), MSH2, MSH6 (10%), EPCAM gene
Disease course:
- 70 – 80% of affected individuals will develop CRC
- Mean age of colorectal cancer at age 40 – 45 with some presenting in their 20s
Hereditary non-polyposis colorectal cancer (HNPCC)
Clinical manifestations
Diagnostic criteria
CRC:
- Predominant right sided
- Arise from large/ flat/ dysplastic adenomas
- Rapid progression from adenomas
Extra-colonic manifestation
o GI: Gastric/ Pancreas/ Biliary/ Small intestine
o Gyn: Endometrial/ Ovarian
o Uro: Renal/ Ureter
o CNS: Brain (glioma)
o Others: Sebaceous gland
Amsterdam criteria: 3-2-1 rule
- 3 or more relatives with Lynch syndrome associated cancer
- 2 or more successive generations should be affected
- 1 or more cancers were diagnosed before age of 50
- Familial adenomatous polyposis should be excluded in CRC
- Tumour should be verified by pathological examination
Hereditary non-polyposis colorectal cancer (HNPCC)
Investigations and surveillance
Management
Surveillance
- Colonoscopy: Starting at age 20 every 1 year
- OGD with biopsy of gastric antrum: Starting at age 30 every 1 – 2 years
- USG kidney and bladder: Starting at age 30 every 1 – 2 years
- Pelvic examination, endometrial biopsy, ransabdominal/transvaginal USG and CA125: Starting at age 30 every 1 year
Treatment
* Total abdominal colectomy with ileorectal anastomosis (IRA)
* Total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAHBSO)
Colon
Vascular supply and lymphatics
Rectum
Anatomical boundaries
Anatomical features
Divisions
Neurovascular and lymphatics
Anatomical: Measuring 12 – 15 cm long starting from rectosigmoid junction to dentate line
o Radiographic: Sacral promontory is the upper limit of rectum
o Endoscopic: 15 cm from anal verge is the upper limit of rectum
Anatomical: Absence of taeniae coli, epiploic appendices and haustration; NOT suspended by a true mesentery
Mesorectum: perirectal areolar tissue that is thicker posteriorly and contains terminal branches of IMA
Divisions:
- Upper 1/3 = Covered by peritoneum anteriorly and laterally
- Middle 1/3 = Covered by peritoneum anteriorly only
- Lower 1/3 = Completely extra-peritoneal lying below pelvic peritoneum
Anal canal
Anatomical boundaries
Neurovascular and lymphatic supply
Anatomical definition of rectal cancers
Anal canal
* Measuring 4 cm long from the anal verge
* Dentate (Pectinate) line divides upper 2/3 and lower 1/3 of anal canal
Location of rectal cancer
* Lower rectal cancer = 4 – 8 cm from anal verge
* Middle rectal cancer = 8 – 12 cm from anal verge
* Upper rectal cancer = 12 – 15 cm from anal verge
CRC
Pathogenesis pathways
Adenoma-carcinoma sequence (60 – 70% of sporadic cancer): Chromosomal instability pathway
- arise from adenomatous polyps (2/3 all polyps) by accumulation of mutations and transform into adenomas
- Progression from adenoma to carcinoma takes at least 10 years on average
- Villous adenomas are associated with highest malignancy risk: up to 40%
- Other adenomas e.g. tubular, hyperplastic, non-polypoid adenomas have lower risk of malignant change
- Associated genetic changes: Acitvation of K-ras oncogene, Inactivation of APC and p53 tumour suppressor genes, Mutation of MYH repair gene
Microsatellite instability pathway (MSI) (15% of sporadic cancer)
- Strongly associated with HNPCC
- Includes MSH2, MLH1, PMS1, PMS2, MSH6/GTBP
- Instability promotes mutation, genomic instability and ultimately to carcinogenesis
CRC
TNM staging
TNM:
- Stage I = Tumour that is invasive through the muscularis mucosae but are confined to the
submucosa (T1) or muscularis propria (T2) in the ABSENCE of nodal metastasis
- Stage II = Tumour that invades through bowel wall into Subserosa or non-peritonealized pericolic or perirectal tissues (T3) or into other organs or tissues or through the visceral peritoneum (T4) in the ABSENCE of nodal metastasis
- Stage III = Presence of nodal metastasis with any T stage
- Stage IV = Presence of distant metastasis
Duke’s staging (superceded by TNM)
- Duke’s A = Tumour within wall of the bowel
- Duke’s B = Tumour invades through the wall of bowel
- Duke’s C = Presence of regional LN metastasis
- Duke’s D = Presence of distant metastasis
Colorectal polyp
Types and malignant potential
- Inflammatory pseudopolyp: No malignant potential
- Inflammatory reaction to muscosal ulcersations and regenerations in Inflammatory bowel disease - Haramtomatous: No malignant potential
- Juvenile polyp: young onset, might require polypectomy
- Peutz-Jeghers polyps: Associated with the Peutz-Jeghers syndrome (PJS) due to STK11 mutations - Serrated:
- Hyperplastic (most common non-neoplastic polyp): no malignant potential except subtype hyperplastic polyposis
- Sessile serrated polyp/ adenoma (SSP/A): Malignant potential, precursor lesion to sporadic microsatellite
instability-high (MSI-H) colon cancer
- Traditional Serrated Adenoma (TSA): malignant potential, prevalent in rectocigmoid colon
Adenomatous polyp: Malignant potential
- Endoscopic types: Sessile, Flat, Depressed, Pedunculated
- Histological types: Tubular (80% CRC), Villous (5-15% CRC), Tubulovillous (5-15% CRC)
- Malignant potential: Sessile > Pedunculated; Villous > Tubular
Classification for malignant colorectal polyps
Haggitt classification (1985) of pedunculated malignant colorectal polyps
Kudo (Kikuchi) classification of sessile malignant colorectal polyps
High risk features of malignant colonic polyps
High risk feature:
- associated with an increased incidence of LN
metastasis and residual cancer
- need for radical resection
List:
* Poorly differentiated histology
* Lymphovascular invasion
* Inadequate endoscopic resection margin < 2 mm
* T1 lesion with invasion into the lower 1/3 of the submucosa (Sm-3)
* T2 lesion or above with invasion through the muscularis propria
CRC
Clinical presentation
Clinical presentation:
- PR bleeding
- Melena
- Hematochezia
- Abdominal pain
* Partial or complete obstruction
* Peritoneal dissemination
* Intestinal perforation leading to generalized peritonitis
- Abdominal distention
- Change in bowel habit
- Tenesmus
- Diminished caliber of stool
- Lymphadenopathy
-Anemic symptoms - Pallor/ Palpitations/ Dyspnea
- Constitutional symptoms
- Nausea and vomiting
- Anorexia and weight loss
CRC
Investigations
Biochemical
- CBC with differential: Anaemia of various cases
- Iron profile: IDA
- LFT: liver metastasis, nutritional status via albumin level
- RFT: contrast imaging, dehydration/ hypovolemia
- CEA level: Pre-operative checkup to facilitate surgical planning, baseline and Post-operative follow-up to detect recurrence or metastasis, Assessment of prognosis
- Genetic test: Molecular profiling for microsatellite instability (MSI)/ deficient DNA mismatch repair (dMMR) - MSI/dMMR phenotype has poorer differentiation, different response to adjuvant 5-FU, better prognosis in stage-adjusted survival
Imaging:
- Colonoscopy: localize and biopsy lesions
- CT virtual colonoscopy: Indicated in incomplete colonoscopy due to mechanical obstruction or patient’s intolerance
- Double-contrast barium enema is used (DCBE)/ Gastrografin contrast enema: Indicated when colonoscopy is unsuccessful due to intestinal obstruction; “Apple-core” appearance
Staging investigations:
- CXR: cardiopulmonary diseases, metastatic lesions
- CT chest + abdomen + pelvis (T + A + P): demonstrate tumour extension, regional lymphatic and distant metastasis and tumour-related complications
- CT chest and MRI liver
- Transrectal ultrasound (TRUS) for staging rectal tumors to evaluate depth of invasion, circumferential resection margin (CRM) and LN status to determine need of neoadjuvant chemoradiation
- MRI rectum: assess mesorectal involvement for neoadjuvant chemoirradiation
- PET scan (FDG): distant metastasis and recurrence in follow-up
CRC
Medical treatment options
Predictive biomarker testing:
- KRAS screening: Wild-type KRAS has a favorable response to EGFR-targerted therapies - cetuximab or panitumumab. Mutant KRAS will NOT benefit
- BRAF screening: Mutant BRAF is unlikely to benefit from cetuximab or panitumumab
Medical treatment:
Cytotoxic chemotherapy: Indicated for all stage III and high-risk stage II disease (e.g. T4 stage, poor differentiation, perineural or lymphovascular invasion)
- 5-fluorouracil/ leucovorin (5-FU) (OR)
capecitabine (Xeloda) + oxaliplatin (OR) irinotecan
- S/E: Mucositis/ Nausea and vomiting/ Diarrhea/ Febrile neutropenia/ Alopecia/ Hand-foot syndrome
Anti-VEGF monocolonal antibodies: indicated only for stage IV metastatic disease
- Add-on therapy to chemotherapy for KRAS/ BRAF mutations
- Bevacizumab (OR) Aflibercept (OR) Regorafenib
Anti-EGFR monoclonal antibodies: indicated only for stage IV metastatic disease
- Add-on therapy for Irinotecan-based chemotherapy for Wild-type KRAS/ BRAF
- Cetuximab (OR) Panitumumab
CRC - colon cancer
Surgical treatment options
Goals:
- Complete removal of tumour with adequate proximal and distal margin (at least 5cm)
- High ligation of arterial pedicle for LN clearance
- Tension-free anastomosis
- Good anastomotic/ stoma blood supply
LN resection for staging: minimum of 12 lymph nodes
Stage-specific treatment:
- Stage I = Surgical resection
- Stage II = Surgical resection ± Adjuvant chemotherapy for high risk factors (young patients, inadequate LN retrieval (< 12) or tumours with “high-risk” histological findings)
- Stage III = Surgical resection + Adjuvant chemotherapy (improves survival due to LN involvement, except patients with MSI-high stage III disease)
- Stage IV = Resection in highly selected patients + Adjuvant chemotherapy/ Palliative procedures
Patient selection in Stage IV disease:
- Liver metastasis: only 20% of metastasis confined to liver is potentially resectable for cure. All patients with liver met need adjuvant chemotherapy
- Lung metastasis: only 2% of metastasis is resectable for cure
Palliative care:
- Colonic stenting/ Diverting stoma/ Bypass surgery for obstruction
- Angiographic embolization for hemorrhage
- External beam irradiation
Extents of bowel resection
General rule: malignancy indicates ligation of vessels at their origin
- Segmental colectomy: cut descending colon with left colic branches
- Ileocecectomy: cut distal ileum and cecum with ileal branch of ileocolic artery
- Right hemicolectomy (benign): cut distal ileum, cecum, ascending colon, transverse colon to the right of middle colic artery + ileal and colic branches of ileocolic artery + right colic artery + branch of middle colic artery
- Right hemicolectomy (malignant): cut distal ileum, cecum and ascending colon, transverse colon to the right of middle colic artery + ORIGIN of ileocolic, right colic, middle colic artery and vein
- Extended right hemicolectomy: same as right hemocolectomy (malignant) + extend towards splenic flexure of transverse colon
- Transverse colectomy (usually do extended right hemicolectomy instead): cut from hepatic to splenic flexure of transverse colon, root of middle colic and left colic arteries
- Left hemicolectomy (benign): cut splenic flexure of transverse colon, descending colon and sigmoid colon above rectosigmoid junction + Branches of left colic artery + branches of sigmoid artery
- Left colectomy (malignant): cut splenic flexure of transverse colon, descending colon, and sigmoid colon below rectosigmoid junction + Origin of IMA and IMV
- Total colectomy: entire intraperitoneal colon from terminal ileum to below rectosigmoid junction with associated mesentery + All mesenteric vessels ligated close to origin
Compare open vs laparoscopic vs robotic colectomy
Laparoscopic colectomy:
- Uncomplicated localized colorectal
cancer
- No prior extensive abdominal surgery
Open colectomy:
- complicated colorectal cancer
Choice of colectomy for benign, malignant lesions and malignant polyps
Benign:
- Segmental colectomy, Left or right hemicolectomy
- Diverticular disease: Sigmoidectomy or Left hemicolectomy if descending colon cannot anastomose
- Mesenteric vessels are ligated blose to mesenteric border of colon
- Unnecessary to resect draining lymph node
Malignant lesions:
- Cecum, appendix, ascending colon: Right hemicolectomy
- Hepatic flexure, proximal to mid-transverse colon: Extended right hemicolectomy
- Distal transverse colon, splenic flexure or descending colon: Left hemicolectomy
- Sigmoid colon: sigmoidectomy
- Complete mesocolic resection + ligation of mesenteric vessels close to origin to optimally resect lymphovascular tissue
Malignant polyp:
- Indicated for types of Sessile polyps and adenomatous polyps with malignant potnetial
- High risk features: poorly differentiated histology, lymphovascular invasion, cancer at
resection or stalk margin, invasion into muscularis propria (T2 lesion), sessile polyp with lower third submucosal penetration